We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Discovery About Biologic Clocks

By HospiMedica staff writers
Posted on 25 Jul 2006
A new study offers insight on a mutation in the gene that regulates circadian rhythm, causing scientists to change their approach in designing new drugs to treat sleep disorders, depression, jet lag, and other biologic clock disorders.

Researchers from the Huntsman Cancer Institute at the University of Utah (Salt Lake City, USA) and the University of Michigan (Ann Arbor, USA) examined the so-called tau mutation that causes hamsters to have a 20-hour day instead of a 24-hour day. More...
The researchers discovered that what was previously believed about the tau mutation--that a decrease in gene activity sped up a mammal's internal clock--was incorrect, and that in fact, the opposite was true; the mutation caused an increase in gene activity to speed up the clock, making the day two to four hours shorter for affected animals. The study was published in the July 3, 2006, online edition of the Proceedings of the [U.S.]National Academy of Sciences.

Previous work had indicated that the tau mutation occurred in a gene called casein kinase 1 epsilon (CK1) and that the mutation caused an 85% loss of gene activity. A computer simulation by University of Michigan mathematician Daniel Forger, Ph.D., an assistant professor of mathematics, concluded that the mutant CK1 gene would cause PER, one of the proteins responsible for running the biologic clock, to dissipate more quickly, triggering a new day cycle. Upon trial, the model proved correct: the circadian rhythm within the mouse cells did speed up, explaining why a day for an animal with the tau mutation would last only 20 hours.

"The key to developing treatments for problems like depression and insomnia--disorders influenced by circadian rhythm--is being able to predict how the body's internal clock can be controlled,” said David Virshup, M.D., of the Huntsman Cancer Institute, co-principal investigator on the project. "If the working model is wrong, drugs will have the opposite effect.”

Biologic clocks with a circadian rhythm period of approximately 24 hours exist in most organisms and time a variety of functions, including sleep-wake cycles, hormone release, bioluminescence, and core body temperature fluctuations. Disruption of these circadian rhythms has been linked to cancer and diabetes, as well as depression and sleep disorders.




Related Links:
Huntsman Cancer Institute
University of Michigan

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.